Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Media Coverage
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Evaluate Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us at media@evaluate.com.
Latest Media Coverage
Nature Reviews Drug Discovery
Top companies and drugs by sales in 2020
Having supplanted Novartis as the biggest pharma company by prescription sales in 2019, Roche managed to hang onto the title in 2020.
Wall Street Journal
FTC Prepares to Take Tougher Stance on Pharmaceutical Mergers
There were more than 900 pharmaceutical deals valued at about $800 billion between 2016 and 2020, according to a market-research firm, EvaluatePharma.
The Times
Siggi Olafsson interview — Trump’s medicine man rides the storm
Global sales of generics are expected to reach $100 billion by 2024, according to the research firm EvaluatePharma, up from $75 billion in 2018.
Browse the archive
The Pharma Letter
The rationale behind Lilly’s $1.1 billion takeover of Dermira
Evaluate Pharma forecasts Aimovig to maintain its lead up to 2024, with estimated sales of $2.05bn that year. It also predicts Emgality could hit $1.2bn by 2024.
PMLive
Roche builds case for SMA drug risdiplam as FDA verdict nears
EvaluatePharma has predicted that risdiplam could become an $800m-plus drug by 2024, and other analysts have said it could make upwards of $2.5bn at its peak.
PMLive
Biogen triumphs over Mylan’s Tecfidera patent challenge
For comparison, while Tecfidera is a billion-dollar product, EvaluatePharma has forecast sales of Vumerity to reach a modest $111m in 2024.
Fortune
Nestlé invests another $200 million in Aimmune’s peanut allergy drug
Evaluate Pharma projects that Palforzia could be a blockbuster drug that brings in more than $1 billion in annual sales by 2024.
PMLive
Lilly launches migraine med Reyvow at $640 per eight-pill pack
Evaluate Pharma forecasts Aimovig to maintain its lead up to 2024, with estimated sales of $2.05bn that year. It also predicts Emgality could hit $1.2bn by 2024, with…
FiercePharma
Aimmune's controversial peanut allergy med has its FDA nod. Will it sell?
And according to Evaluate Pharma, it's a blockbuster approval. Palforzia could hit an estimated $1.28 billion in sales by 2024, the firm said, as an immunotherapy that…
Pharmaphorum
Lilly keeps ahead of Blueprint with swift FDA review for selpercatinib
EvaluatePharma has said selpercatinib could become a $500 million-plus product by 2024.
FierceBiotech
After NASH flops, Conatus becomes Histogen via reverse merger
Conatus’ fate “serves to underline the risks of NASH,” Vantage wrote in June after its pan-capsase inhibitor, emricasan, failed its third NASH study.
PMLive
Troubled Alkermes eyes November OK for new antipsychotic
EvaluatePharma has previously predicted that sales of ALKS 381 could reach $381m in 2024 if approved, which would be a sizeable addition to its current revenues, expected…
The Pharma Letter
Report suggests industry overcoming patent cliff challenge
Projections from EvaluatePharma are quoted by the study, showing that the sector will experience compound annual growth of 6.9% for global prescription drug sales.
